Teitur Trophics

All Fund articles Fund PR Portfolio articles Portfolio PR

Teitur Trophics announces successful results from Phase I clinical trial of first-in-class Parkinson’s disease peptide TT-P34

2026.09.102026.09.10 / · Study shows TT-P34 is safe and well tolerated in healthy volunteers and patients with early-stage Parkinson’s disease (PD), with pharmacokinetics confirming robust CNS exposure · Early ...

Simon Mølgaard Named Rising Star in Danish Biotech

2026.06.292026.06.29 / We are proud to congratulate Simon Mølgaard, CEO of our portfolio company Teitur Trophics, on being awarded the Rising Star in Danish Biotech at the Biotech Spring Gala — with the recognition display ...

Teitur Trophics CEO Simon Mølgaard Receives Rising Star Award at Biotech Spring Gala

2026.05.072026.05.18 / We are pleased to congratulate Simon Mølgaard, CEO of Teitur Trophics, on receiving the Rising Star Award at this year’s Biotech Spring Gala. The award, presented by DANISH BIO – Dansk Biotek, rec ...

Teitur Trophics Initiates Dosing of First Parkinson’s Disease Patient in Clinical Trial at CHDR, Leiden

2026.01.262026.01.26 / Teitur Trophics today announce the dosing of the first two patients with Parkinson’s disease in the Phase I trial for TT-P34, conducted at the Centre for Human Drug Research (CHDR) in Leiden, the Net ...

Teitur Trophics Initiates First Clinical Trial in Patients with Parkinson’s Disease

2026.01.262026.01.26 / Teitur Trophics is pleased to announce the initiation of its first clinical trial in patients with Parkinson’s disease. The study marks an important milestone in the company’s ongoing Phase I clinica ...

The drive to adapt a lab discovery into treatment of neurodegeneration

2023.03.292024.05.13 / Teitur Trophics is breaking new ground when it comes to neurodegenerative diseases. After identifying a previously unknown means of preserving functioning brain cells, the biotech company’s founders ...

Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases

2023.03.142024.09.11 / Financing co-led by Sunstone Life Science Ventures and Sound Bioventures with participation from Industrifonden, Innovestor’s Life Science Fund and P53 Invest Discovery of a novel mechanism with ...